Shares of Sanofi SA (NYSE:SNY) have been given a consensus recommendation of “Buy” by the thirteen analysts that are presently covering the company, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $49.67.

A number of analysts have commented on the stock. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Tuesday, August 6th. Sanford C. Bernstein began coverage on shares of Sanofi in a research note on Tuesday, September 3rd. They issued an “outperform” rating and a $52.00 target price for the company. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Friday, June 21st. UBS Group upgraded shares of Sanofi from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 14th. Finally, Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Thursday, August 29th.

SNY stock traded down $0.09 during midday trading on Friday, reaching $43.71. 2,063,000 shares of the company’s stock traded hands, compared to its average volume of 1,243,294. The company has a market cap of $109.48 billion, a price-to-earnings ratio of 13.96, a P/E/G ratio of 2.41 and a beta of 0.67. The firm’s fifty day moving average price is $42.61 and its 200-day moving average price is $42.72. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. Sanofi has a 52 week low of $40.00 and a 52 week high of $45.62.

Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 29th. The company reported $0.74 EPS for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.07. The business had revenue of $8.63 billion during the quarter, compared to analyst estimates of $8.42 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. Sanofi’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.25 EPS. Analysts forecast that Sanofi will post 3.1 earnings per share for the current year.

In other news, major shareholder Sanofi sold 172,904 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total value of $48,611,959.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.00% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. NumerixS Investment Technologies Inc boosted its holdings in shares of Sanofi by 218.8% in the 1st quarter. NumerixS Investment Technologies Inc now owns 17,800 shares of the company’s stock worth $788,000 after buying an additional 12,216 shares during the last quarter. Cetera Advisors LLC purchased a new position in shares of Sanofi in the 2nd quarter worth about $293,000. Sontag Advisory LLC purchased a new position in shares of Sanofi in the 2nd quarter worth about $284,000. Coastal Investment Advisors Inc. boosted its holdings in shares of Sanofi by 96.1% in the 2nd quarter. Coastal Investment Advisors Inc. now owns 3,251 shares of the company’s stock worth $139,000 after buying an additional 1,593 shares during the last quarter. Finally, Dearborn Partners LLC purchased a new position in shares of Sanofi in the 2nd quarter worth about $251,000. Hedge funds and other institutional investors own 7.04% of the company’s stock.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Story: Why is the ex-dividend date different from the record date?

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.